The Nanomol-bio research group (ICMAB-CSIC and CIBER-BBN) celebrates the creation of DELBIOS Pharmaceuticals SL, a new technology-based spin-off founded by researchers from our group, which has recently secured NEOTEC 2025 funding from CDTI. This milestone represents a significant step in Nanomol-bio’s long-standing commitment to technology transfer and the translation of nanomedicine research into real clinical impact.
DELBIOS was established with a clear mission: to accelerate the progression of nanomedicines from advanced preclinical stages to early clinical development. The company’s model is specifically designed to bridge the gap that often exists between academic research and the pharmaceutical market, focusing on high-value therapeutic candidates that address unmet medical needs.
At the core of DELBIOS lies a licensing-based and development-driven business model. The company acquires licenses for patents and technologies originating from cutting-edge research—particularly from Nanomol-bio and its collaborative ecosystem—and further develops these assets to a level where they can be partnered or licensed to pharmaceutical companies. This approach allows robust scientific innovations to move efficiently along the translational pathway while maintaining strong links with the academic environment in which they were created.
A company founded from Nanomol-bio expertise
DELBIOS was founded in 2024 by Nanomol-bio researchers Nora Ventosa, Elisabet González and Judit Tomsen, together with members of Nanomol Technologies SL, another Nanomol-bio spin-off, including Santi Sala and Alba Córdoba. The founding team combines deep expertise in nanotechnology and drug delivery with experience in innovation management and entrepreneurship, forming a solid basis for a sustainable and impact-oriented spin-off.
The company is located at the UAB Research Park, within a vibrant innovation ecosystem that fosters collaboration between research institutions, start-ups and industry. DELBIOS also builds on experience gained through participation in European initiatives such as Nano4Rare, a project focused on developing a nanomedicine for the treatment of Fabry disease, further reinforcing its translational and patient-oriented vision.
Strengthening technology transfer in nanomedicine
With the support of NEOTEC 2025 funding, DELBIOS will consolidate its operational structure and advance its portfolio of nanomedicine candidates, strengthening its role as a bridge between Nanomol-bio research and the pharmaceutical industry. From Nanomol-bio, we are proud to see our research give rise to new entrepreneurial initiatives and we strongly support DELBIOS as a clear example of how academic science can be transformed into innovative therapeutic solutions with societal impact.
